Novavax (NVAX) Amortization of Deferred Charges (2016 - 2020)
Novavax has reported Amortization of Deferred Charges over the past 5 years, most recently at $356000.0 for Q4 2020.
- Quarterly results put Amortization of Deferred Charges at $356000.0 for Q4 2020, changed 0.0% from a year ago — trailing twelve months through Dec 2020 was $1.4 million (changed 0.0% YoY), and the annual figure for FY2020 was $1.4 million, changed 0.0%.
- Amortization of Deferred Charges for Q4 2020 was $356000.0 at Novavax, roughly flat from $356000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for NVAX hit a ceiling of $357000.0 in Q4 2017 and a floor of $237000.0 in Q1 2016.
- Median Amortization of Deferred Charges over the past 5 years was $356000.0 (2016), compared with a mean of $349789.5.
- Biggest five-year swings in Amortization of Deferred Charges: soared 50.21% in 2017 and later dropped 0.28% in 2018.
- Novavax's Amortization of Deferred Charges stood at $356000.0 in 2016, then increased by 0.28% to $357000.0 in 2017, then dropped by 0.28% to $356000.0 in 2018, then changed by 0.0% to $356000.0 in 2019, then changed by 0.0% to $356000.0 in 2020.
- The last three reported values for Amortization of Deferred Charges were $356000.0 (Q4 2020), $356000.0 (Q3 2020), and $356000.0 (Q2 2020) per Business Quant data.